» Articles » PMID: 21984372

CD24 Promotes Tumor Cell Invasion by Suppressing Tissue Factor Pathway Inhibitor-2 (TFPI-2) in a C-Src-dependent Fashion

Overview
Specialty Oncology
Date 2011 Oct 11
PMID 21984372
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

CD24 is a glycosyl-phosphatidylinositol-anchored protein with mucin-type structure that resides exclusively in membrane microdomains. CD24 is often highly expressed in carcinomas and correlates with poor prognosis. Experimentally, the over-expression or depletion of CD24 alters cell proliferation, adhesion, and invasion in vitro and tumor growth in vivo. However, little is known about the mechanisms by which CD24 mediates these cellular effects. Here we have studied the mechanism of CD24-dependent cell invasion using transient CD24 knock-down or over-expression in human cancer cell lines. We show that CD24 depletion reduced tumor cell invasion and up-regulated expression of Tissue Factor Pathway Inhibitor 2 (TFPI-2), a potent inhibitor of extracellular matrix degradation that can block metastases formation and tumor cell invasion. Over-expression of CD24 in A125 cells resulted in reduced TFPI-2 expression and enhanced invasion. We provide evidence that the activity of c-Src is reduced upon CD24 knock-down. The silencing of c-Src, similar to CD24, was able to enhance TFPI-2 expression and reduce tumor cell invasion. An inverse expression of CD24 and TFPI-2 was observed by immunohistochemical analysis of primary breast cancers (N = 1,174). TFPI-2 expression was highest in CD24 negative samples and lowered with increasing CD24 expression. Patients with a CD24 low/TFPI-2 high phenotype showed significantly better survival compared to CD24 high/TFPI-2 low patients. Our results provide evidence that CD24 can regulate cell invasion via TFPI-2 and suggests a role of c-Src in this process.

Citing Articles

From mechanism to therapy: the journey of CD24 in cancer.

Zhao K, Wu C, Li X, Niu M, Wu D, Cui X Front Immunol. 2024; 15:1401528.

PMID: 38881902 PMC: 11176514. DOI: 10.3389/fimmu.2024.1401528.


Effects of DNA methylation and its application in inflammatory bowel disease (Review).

Akanyibah F, Zhu Y, Wan A, Ocansey D, Xia Y, Fang A Int J Mol Med. 2024; 53(6).

PMID: 38695222 PMC: 11093555. DOI: 10.3892/ijmm.2024.5379.


Surprising magic of CD24 beyond cancer.

Wang H, Shi P, Shi X, Lv Y, Xie H, Zhao H Front Immunol. 2024; 14:1334922.

PMID: 38313430 PMC: 10834733. DOI: 10.3389/fimmu.2023.1334922.


New hope for tumor immunotherapy: the macrophage-related "do not eat me" signaling pathway.

Deng H, Wang G, Zhao S, Tao Y, Zhang Z, Yang J Front Pharmacol. 2023; 14:1228962.

PMID: 37484024 PMC: 10358856. DOI: 10.3389/fphar.2023.1228962.


The biological roles of CD24 in ovarian cancer: old story, but new tales.

Gu Y, Zhou G, Tang X, Shen F, Ding J, Hua K Front Immunol. 2023; 14:1183285.

PMID: 37359556 PMC: 10288981. DOI: 10.3389/fimmu.2023.1183285.


References
1.
Varma R, Mayor S . GPI-anchored proteins are organized in submicron domains at the cell surface. Nature. 1998; 394(6695):798-801. DOI: 10.1038/29563. View

2.
Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H . Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem. 2007; 282(25):18634-18644. DOI: 10.1074/jbc.M609567200. View

3.
Dauer D, Ferraro B, Song L, Yu B, Mora L, Buettner R . Stat3 regulates genes common to both wound healing and cancer. Oncogene. 2005; 24(21):3397-408. DOI: 10.1038/sj.onc.1208469. View

4.
Woodward W, Sulman E . Cancer stem cells: markers or biomarkers?. Cancer Metastasis Rev. 2008; 27(3):459-70. DOI: 10.1007/s10555-008-9130-2. View

5.
Senner V, Sturm A, Baur I, Schrell U, Distel L, Paulus W . CD24 promotes invasion of glioma cells in vivo. J Neuropathol Exp Neurol. 1999; 58(8):795-802. DOI: 10.1097/00005072-199908000-00002. View